BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 556 filers reported holding BIO-TECHNE CORP in Q3 2021. The put-call ratio across all filers is 1.21 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $38 | +8.6% | 468 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $35 | -94.9% | 468 | -94.7% | 0.00% | -95.7% |
| Q4 2022 | $682 | -99.9% | 8,782 | +289.1% | 0.02% | 0.0% |
| Q3 2022 | $641,000 | -18.0% | 2,257 | 0.0% | 0.02% | -8.0% |
| Q2 2022 | $782,000 | -20.0% | 2,257 | 0.0% | 0.02% | 0.0% |
| Q1 2022 | $977,000 | -16.4% | 2,257 | 0.0% | 0.02% | -55.4% |
| Q4 2021 | $1,168,000 | +6.8% | 2,257 | 0.0% | 0.06% | +69.7% |
| Q3 2021 | $1,094,000 | +13.5% | 2,257 | +5.5% | 0.03% | 0.0% |
| Q2 2021 | $964,000 | – | 2,140 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ROWLANDMILLER & PARTNERS.ADV | 47,975 | $3,701,751 | 0.85% |
| Diversified Trust Co | 13,882 | $1,071,135 | 0.04% |
| Czech National Bank | 27,698 | $2,137,178 | 0.03% |
| FULTON BANK, N.A. | 5,444 | $420,058 | 0.02% |
| DnB Asset Management AS | 27,637 | $2,132,471 | 0.01% |
| Versant Capital Management, Inc | 36 | $2,778 | 0.00% |
| MASSMUTUAL TRUST CO FSB/ADV | 371 | $28,626 | 0.00% |
| Bartlett & Co. LLC | 172 | $13 | 0.00% |